Nanion Corporate Blog

 

20.09.2019: Recent publication on the downregulation of miR-146a

We as Nanion Technologies would like to congratulate Li Shen and the co-authors of this insightful paper. The paper shows that sunitinib downregulates miR-146a, thereby contributing to cardiac contractile dysfunction by targeting PLN and ANK2. miR-146a could thus, be a useful protective agent against sunitinib-induced cardiac dysfunction. We are honoured that the group from the Pharmacology department of the Hebei Medical University, China used among other assays, the Cardioexcyte 96 for this study.

Download the publication here

Back to Overview

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies).

You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.